The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
基本信息
- 批准号:8653526
- 负责人:
- 金额:$ 38.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntigen ReceptorsAntigensApoptoticApplications GrantsAutoimmune DiseasesB-LymphocytesBiological MarkersBiological ModelsCell LineCell SurvivalCell modelCell physiologyCellsChronicCytokine ReceptorsDataEffector CellEnzymesFamilyFamily memberGenerationsGraft RejectionHypersensitivityImmuneImmune responseImmunityImmunologic ReceptorsIn VitroInfectionInfectious AgentInflammationLigationLymphocyteLymphoidMaintenanceMammalsMeasuresMemoryMethodsMusNF-kappa BOrganPathway interactionsPharmaceutical PreparationsProliferatingProteinsReactionRecombinantsRefractoryRegulationRegulatory T-LymphocyteRoleSignal PathwaySignal TransductionStagingSyndromeSystemT cell differentiationT memory cellT-LymphocyteT-Lymphocyte SubsetsTNFRSF8 geneTestingTimeTissuesTransgenic MiceTransgenic OrganismsTumor Necrosis Factor ReceptorVaccinesWorkcancer immunotherapycytokinedesigndimerflygraft vs host diseasehigh voltage electron microscopyin vivomembermicrobialoverexpressionprototypepublic health relevancereceptorresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): In lymphocytes, signals from antigen, cytokine, and innate immune receptors cause immediate, transient activation of NF-:B through the canonical pathway by triggering IkB degradation. A second, non-canonical or "alternative" NF-kB pathway has been described downstream of some members of the TNFR family. Slow, sustained activation of NF-kB through this IkB-independent, NIK-dependent non-canonical pathway governs the formation of secondary lymphoid organs (downstream of LT2R) and determines the fate of B cells (downstream of BAFFR). Almost nothing is known of the role of the non-canonical NF-kB pathway in T cell function, although T cells express a number of costimulatory TNFR family members, including OX40, 4-1BB, CD27, GITR, CD30, and HVEM, that have been shown to activate the non-canonical pathway in transfected cell lines, and that are known to provide essential signals for function and survival of activated T cells after antigen recognition. The working hypothesis of this proposal is that sustained activation of NF-kB through the non-canonical pathway downstream of these TNFR family members is necessary for induction and maintenance of expression of the cytokines, cytokine receptors, and anti-apoptotic proteins that allow T cells to survive and function as differentiated effector and memory cells. The proposed experiments are designed to determine whether the non-canonical pathway is activated downstream of the costimulatory TNFR family members in T cells, whether it is necessary for the costimulatory activity of TNFR family members in vivo, and whether independent activation of that pathway mimics some of the costimulatory activities of the TNFR family members, including blocking the function of regulatory T cells.
描述(由申请人提供):在淋巴细胞中,来自抗原、细胞因子和先天免疫受体的信号通过典型途径引发IKB降解,立即、短暂地激活核因子-B。在TNFR家族的一些成员下游,已经描述了第二个非典范或“替代”的NF-kB途径。通过这种IKB非依赖、NIK依赖的非规范途径缓慢、持续地激活NF-kB,控制着次级淋巴器官(LT2R下游)的形成,并决定B细胞(BAFFR下游)的命运。尽管T细胞表达许多共刺激的TNFR家族成员,包括OX40、4-1BB、CD27、GITR、CD30和HVEM,但几乎没有人知道非规范的NF-kB途径在T细胞功能中的作用,这些成员被证明在转基因细胞系中激活了非规范的途径,并被认为是在抗原识别后为激活的T细胞的功能和生存提供必要的信号。这一建议的工作假设是,通过这些TNFR家族成员下游的非规范途径持续激活NF-kB,对于诱导和维持细胞因子、细胞因子受体和抗凋亡蛋白的表达是必要的,这些蛋白允许T细胞存活并作为分化的效应细胞和记忆细胞发挥作用。这些实验旨在确定T细胞中非正则途径是否在共刺激的TNFR家族成员下游被激活,它是否是体内TNFR家族成员的共刺激活性所必需的,以及该途径的独立激活是否模仿了TNFR家族成员的一些共刺激活动,包括阻断调节性T细胞的功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID C PARKER其他文献
DAVID C PARKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID C PARKER', 18)}}的其他基金
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8261672 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8460461 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
The non-canonical NF-kappaB pathway in survival and function of T lymphocytes
T 淋巴细胞存活和功能中的非经典 NF-kappaB 通路
- 批准号:
8186294 - 财政年份:2011
- 资助金额:
$ 38.5万 - 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
- 批准号:
7364592 - 财政年份:2007
- 资助金额:
$ 38.5万 - 项目类别:
The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
- 批准号:
7487426 - 财政年份:2007
- 资助金额:
$ 38.5万 - 项目类别:
B Cell Subsets as Antigen-presenting Cells in Peripheral Self-tolerance
B 细胞亚群作为外周自我耐受中的抗原呈递细胞
- 批准号:
7266093 - 财政年份:2007
- 资助金额:
$ 38.5万 - 项目类别:
The Alternative NFkB Pathway in Survival and Function of Anti-Viral T Cells
抗病毒 T 细胞存活和功能中的替代 NFkB 途径
- 批准号:
7391936 - 财政年份:2007
- 资助金额:
$ 38.5万 - 项目类别:
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10321545 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别: